Volume 14, Number 4—April 2008
Murine Typhus, Algeria
Highlight and copy the desired format.
|EID||Mouffok N, Parola P, Raoult D. Murine Typhus, Algeria. Emerg Infect Dis. 2008;14(4):676-678. https://dx.doi.org/10.3201/eid1404.071316|
|AMA||Mouffok N, Parola P, Raoult D. Murine Typhus, Algeria. Emerging Infectious Diseases. 2008;14(4):676-678. doi:10.3201/eid1404.071316.|
|APA||Mouffok, N., Parola, P., & Raoult, D. (2008). Murine Typhus, Algeria. Emerging Infectious Diseases, 14(4), 676-678. https://dx.doi.org/10.3201/eid1404.071316.|
To the Editor: Rickettsioses, or typhoid diseases, are caused by obligate intracellular bacteria of the order Rickettsiales. The ubiquitous murine typhus is caused by Rickettsia typhi. Although cat fleas and opposums have been suggested as vectors in some places in the United States, the main vector of murine typhus is the rat flea (Xenopspylla cheopis), which maintains R. typhi in rodent reservoirs (1). Most persons become infected when flea feces containing R. typhi contaminate broken skin or are inhaled, although infections may also result from flea bites (1). Murine typhus is often unrecognized in Africa; however, from northern Africa, 7 cases in Tunisia were documented in 2005 (2).
We conducted a prospective studyin Algeria which included all patients who had clinical signs leading to suspicion of rickettsioses (high fever, skin rash, headache, myalgia, arthralgia, eschar, or reported contact with ticks, fleas, or lice) who visited the Oran Teaching Hospital in 2004–2005 for an infectious diseases consultation. Clinical and epidemiologic data as well as acute-phase (day of admission) and convalescent-phase (2–4 weeks later) serum samples were collected. Serum samples were sent to the World Health Organization Collaborative Center for Rickettsial Diseases in Marseille, France. They were tested by immunofluoresence assay (IFA), by using spotted fever group (SFG) rickettsial antigens (R. conorii conorii, R. conorii israelensis, R. sibirica mongolitimonae, R. aeschlimmanii, R. massiliae, R. helvetica, R. slovaca, and R. felis) and R. typhi and R. prowazekii as previously reported (3). When cross-reactions were noted between several rickettsial antigens, Western blot (WB) assays and cross-absorption studies were performed as previously described (4). A total of 277 patients were included. We report 2 confirmed cases of R. typhi infection in patients from Algeria.
The first patient, a 42-year-old male pharmacist who reported contact with cats and dogs parasitized by ticks, consulted with our clinic for a 10-day history of high fever, sweating, headache, arthralgia, myalgia, cough, and a 6-kg weight loss. He had not received any antimicrobial drugs before admission. No rash, eschar, or specific signs were found. Standard laboratory findings were within normal limits. No acute-phase serum sample was sent for testing. However, IFAs on convalescent-phase serum were negative for SFG antigens (except R. felis: immunoglobulin [Ig] G 64, IgM 128), but they showed raised antibodies against R. typhi and R. prowazekii (IgG 2,048, IgM 1,024).
The second patient, a 25-year-old farmer, was hospitalized for a 5-day history of fever, headache, diarrhea, and lack of response to treatment with amoxicillin and acetaminophen. He reported contact with cats and cattle. A discrete macular rash and pharyngitis were observed. Standard laboratory findings were within normal limits, except neutrophil count was elevated at 11.2/μL (normal levels 3–7/μL). Acute-phase serum was negative for rickettsial antigens. Convalescent-phase serum obtained 2 weeks later was positive for several SFG antigens (IgM only; the highest level was 256 for R. conorii), and higher levels of antibodies were obtained against R. typhi and R. prowazekii (IgG 256, IgM 256). WB and cross-absorption studies confirmed R. typhi infection (Figure). Both patients recovered after a 3-day oral doxycycline regimen and have remained well. (A single 200-mg dose of oral doxycycline usually leads to defervescence within 48–72 hours ).
Murine typhus is a mild disease with nonspecific signs. Less than half of patients report exposure to fleas or flea hosts. Diagnosis may be missed because the rash, the hallmark for rickettsial diseases, is present in <50% of patients and is often transient or difficult to observe. Arthralgia, myalgia, or respiratory and gastrointestinal symptoms, as reported here, are frequent; neurologic signs may also occur (5). As a consequence, the clinical picture can mimic other diseases. A review has reported 22 different diagnoses that were proposed for 80 patients with murine typhus in the United States (6).
Serologic tests are the most frequently used and widely available methods for diagnosis of rickettsioses (7). IFA is the reference method (7). However, R. typhi may cross-react with other rickettsial antigens, including SFG rickettsiae, but especially with the other typhus group rickettsia, R. prowazekii, the agent of epidemic typhus (8). Epidemic typhus is transmitted by body lice and occurs more frequently in cool areas, where clothes are infrequently changed, and particularly during human conflicts. It is still prevalent in Algeria (9).
This cross-reactivity led to some difficulties in interpreting serologic results (10). However, WB and cross-adsorption studies can be used when cross-reactions occur between rickettsial antigens. They are useful for identifying the infecting rickettsia to the species level and for providing new data about the emergence or reemergence of rickettsioses, as reported here. These assays are, however, time-consuming and only available in specialized reference laboratories.
Clinicians need to be aware of the presence murine typhus in Algeria, especially among patients with unspecific signs and fever of unknown origin. Tetracyclines remain the treatment of choice.
- Raoult D, Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev. 1997;10:694–719.
- Letaief AO, Kaabia N, Chakroun M, Khalifa M, Bouzouaia N, Jemni L. Clinical and laboratory features of murine typhus in central Tunisia: a report of seven cases. Int J Infect Dis. 2005;9:331–4.
- Mouffok N, Benabdellah A, Richet H, Rolain JM, Razik F, Belamadani D, Reemergence of rickettsiosis in Oran, Algeria. Ann N Y Acad Sci. 2006;1078:180–4.
- Parola P, Miller RS, McDaniel P, Telford SR III, Wongsrichanalai C, Raoult D. Emerging rickettsioses of the Thai-Myanmar border. Emerg Infect Dis. 2003;9:592–5.
- Gikas A, Doukakis S, Pediaditis J, Kastanakis S, Psaroulaki A, Tselentis Y. Murine typhus in Greece: epidemiological, clinical, and therapeutic data from 83 cases. Trans R Soc Trop Med Hyg. 2002;96:250–3.
- Dumler JS, Taylor JP, Walker DH. Clinical and laboratory features of murine typhus in south Texas, 1980 through 1987. JAMA. 1991;266:1365–70.
- La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol. 1997;35:2715–27.
- La Scola B, Rydkina L, Ndihokubwayo JB, Vene S, Raoult D. Serological differentiation of murine typhus and epidemic typhus using cross-adsorption and Western blotting. Clin Diagn Lab Immunol. 2000;7:612–6.
- Mokrani K, Fournier PE, Dalichaouche M, Tebbal S, Aouati A, Raoult D. Reemerging threat of epidemic typhus in Algeria. J Clin Microbiol. 2004;42:3898–900.
- Parola P, Vogelaers D, Roure C, Janbon F, Raoult D. Murine typhus in travelers returning from Indonesia. Emerg Infect Dis. 1998;4:677–80.
- Figure. Western blot assay and cross-adsorption studies of an immunofluoresence assay–positive serum sample from a patient with rickettsiosis in Algeria. Antibodies were detected at the highest titer (immunoglobulin [Ig] G 256,...
Please use the form below to submit correspondence to the authors or contact them at the following address:
Didier Raoult,Unité des Rickettsies, CNRS UMR 6020, IFR 48, WHO Collaborative Centre for Rickettsial and Arthropod-borne Bacterial Diseases, Faculté de Médecine, Université de la Méditerranée, 27 Blvd Jean Moulin, 13385 Marseilles CEDEX 5, France;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 14, 2010
- Page last updated: July 14, 2010
- Page last reviewed: July 14, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)